Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA (ctDNA) in patients with MIBC who received perioperative durvalumab in NIAGARA.

Baseline ctDNA+ 57% (260/460), pre-RC 22% (94/422).

J Clin Oncol 2025;43(16_suppl):4503.